These samples were part of a larger batch of 200 drugs tested nationwide that were found to be below standard, prompting the ...

Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) reported new late-stage clinical data showing its experimental epilepsy drug EPX-100 delivered sharp and sustained seizure reductions in patients with ...

Individuals with epilepsy and their caregivers want improved communication and a broader base of information from their ...

Glucagon-like peptide-1 receptor agonist therapy is associated with a reduced risk for epilepsy in adults with type 2 diabetes mellitus.

During this symposium, leading international epileptologists discussed the key challenges and opportunities that currently ...

Cassava Sciences shares fell after the company said the Food and Drug Administration had put a hold on its epilepsy drug trial. The stock fell 15% to $2.41 in after-hours trading Thursday. Through the ...

Xenon Pharmaceuticals (XENE) is undervalued given azetukalner's late-stage potential to transform epilepsy and mood disorder ...

Individuals with focal onset epilepsy treated with azetukalner experienced sustained monthly seizure reduction and evidence of seizure freedom up to 48 months, according to data presented at the ...

Taking GLP-1 medications like Ozempic is linked to a smaller risk of developing epilepsy than taking DPP-4 inhibitors. | Drug ...